

Adult Joint
Formulary
Abbreviated
list

February 2022

Contents

Chapter		Page
	Introduction	1
1	Gastro-intestinal system	2
2	Cardiovascular system	4
3	Respiratory system	7
4	Central nervous system	9
5	Infections	13
6	Endocrine system	15
7	Obstetrics, gynaecology and urinary-tract disorders	19
8	Malignant disease and immunosuppression	21
9	Nutrition and blood	23
10	Musculoskeletal and joint diseases	25
11	Eyes	27
12	Ear, nose and oropharynx	30
13	Skin	32
14	Vaccines and immunoglobulins	Not included
15	Anaesthesia	35

Introduction

This NHS Ayrshire & Arran Abbreviated Joint Formulary List includes the names of those medicines recommended within the Joint Formulary - formulations are not specified. The medicines included may have prescribing restrictions, which will be indicated using the following abbreviations:

- | | | |
|-----------------------------|------------------------------|-----------------------------|
| ① First choice within class | ② Second choice within class | ③ Third choice within class |
| H Hospital use | ☑ Consultant initiation | ☑ Specialist initiation |

The full version of the NHS Ayrshire & Arran Joint Formulary should be referred to for further information and local prescribing notes or guidelines that are available. The most current advice on individual medicines from the Scottish Medicines Consortium (www.scottishmedicines.org.uk) should also be applied when prescribing. The full version is maintained and available electronically on the NHS Ayrshire & Arran intranet (AthenA). The current British National Formulary or individual Summary of Product Characteristics (www.medicines.org.uk) should be referred to for dosing advice, adverse effects etc.

Information on the following NHS Ayrshire & Arran policies can be located on both the local internet (www.nhsaaa.net) and intranet (AthenA) sites

- Managed Entry of New Medicines Process
- Individual Patient Treatment Requests
- Formulary Management, including prescribing non-formulary medicines
- Prescribing of unlicensed and “off-label use” of medicines

Updates

The abbreviated Joint Formulary list will be updated monthly and published on the NHS Ayrshire & Arran internet site. In addition the full version of the NHS Ayrshire & Arran Joint Formulary will be updated and is available electronically on the intranet

For further information contact:

Medicines.information@aaaht.scot.nhs.uk

Tel: 01292 614506

- | | | |
|-----------------------------|------------------------------|-----------------------------|
| ① First choice within class | ② Second choice within class | ③ Third choice within class |
| H Hospital use | ☑ Consultant initiation | ☑ Specialist initiation |

1: GASTRO-INTESTINAL SYSTEM

1.1.1 Antacids and simeticone

aluminium hydroxide (*renal only*)
co-magaldrox 195/220 (*Mucogel*®)
Infacol® (*paediatrics only*)

1.1.2 Alginates

① Peptac® suspension
Gaviscon® Infant

1.2 Antispasmodics and other drugs altering gut motility

(a) antispasmodics

hyoscine butylbromide tablets, injection
mebeverine tablets
peppermint oil capsules

1.3 Anti-secretory drugs and mucosal protectants

H₂-receptor antagonists:

① ranitidine

Proton pump inhibitors:

lansoprazole
omeprazole (infusion ☒)
esomeprazole tablets (*refer to full formulary for prescribing restrictions*)

Chelates and complexes

☒ sucralfate

Drugs for the treatment of peptic ulcers

(a) ulcers associated with *Helicobacter pylori*

First choice (for 1 week only):

lansoprazole or omeprazole
+ amoxicillin
+ clarithromycin

Patients allergic to penicillin receive metronidazole instead of amoxicillin in the above regimen

1.4 Acute diarrhoea

① oral rehydration therapy (*acute diarrhoea*)
① loperamide capsules
codeine phosphate
co-phenotrope

1.4.3 Carcinoid Syndrome Diarrhoea

☒ telotristat ethyl tablets

1.5 Chronic bowel disorders

10.5.1 Aminosalicylates

Oral mesalazine preparations

Prescribe mesalazine preparations by brand name

- ① ☒ Salofalk® modified release tablets, sachets
- ② ☒ Octasa® modified release tablets
- ② ☒ Pentasa® sustained release tablets, sachets

Other aminosalicylates preparations

- ☒ mesalazine suppositories
- ☒ mesalazine foam enema
- ☒ sulphasalazine

1.5.2 Corticosteroids

- ① prednisolone tablets (*excludes 25mg strength*), 5mg/5ml oral solution, soluble tablets
- ① prednisolone foam enema
- ① prednisolone retention enema
- ☒ budesonide mr capsules, capsules, granules
- ☒ budesonide prolonged release tablets (*Cortiment® brand for ulcerative colitis as per SMC restrictions*)
- ☒ budesonide rectal foam

1.5.3 Drugs affecting the immune response

Use as per local guideline

- ☒☒ Adalimumab injection (*Amgevita® is brand of choice*)
- ☒☒ Golimumab injection
- ☒☒ Infliximab infusion, injection (*(Remsima® brand of choice)*)
- ☒☒ Ustekinumab injection
- ☒☒ Vedolizumab injection

1.6 Laxatives

(a) bulk forming laxatives

ispaghula husk

(b) stimulant laxatives

① senna
bisacodyl
co-danthramer (*terminally ill patients*)
docusate sodium
glycerol suppositories

(c) faecal softeners

arachis oil enema

(d) osmotic laxatives

lactulose
Laxido® sachets
sodium citrate enema
phosphate enema

① First choice within class

② Second choice within class

③ Third choice within class

☒ Hospital use

☒ Consultant initiation

☒ Specialist initiation

(e) bowel cleansing

- ① Picolax®
- Fleet Phospho-Soda®

Preparations for radiological procedures

Refer to local prescribing guideline (ADTC 263) for additional information.

Bowel Preparation	Imaging Studies
MoviPrep®	Standard preparation for CT Colonoscopy
Picolax®	Standard preparation for Barium Enema
Klean-Prep®	Standard preparation for MRI Small Bowel. Second line for inpatient Barium Enema if unfit for Picolax®

(f) Peripheral opioid receptor antagonists

- ☒ methylnaltrexone
- naloxegol tablets (*Moventig®*)

1.7 Local preparations for anal and rectal disorders

- ① Anusol®
- Anusol-HC®
- Scheriproct® ointment, suppositories

1.9 Drugs affecting intestinal secretions

1.9.1 Drugs affecting biliary composition and flow

- ① ☒ ursodeoxycholic acid
- ☒ obeticholic acid tablets (*case by case form requires to be completed until protocol available*)

1.9.2 Bile acid sequestrants

- ① Colestyramine sachets

1.9.4 Pancreatin

- Creon®
- Creon® micro (*if swallowing problems present*)
- Pancrex V®

2: CARDIOVASCULAR SYSTEM

2.1.1 Cardiac glycosides

- ① digoxin tablets
- ① ☒ digoxin injection

2.1.2 Phosphodiesterase type 3 inhibitors

- ① ☒ ☒ enoximone injection

2.2.1 Thiazide and related diuretics

- ① bendroflumethiazide tablets
- ① indapamide tablets

2.2.2 Loop diuretics

- ① furosemide tablets, injection
- ② bumetanide tablets (*excludes injection*)

2.2.3 Potassium-sparing diuretics and aldosterone antagonists

NYHA class II heart failure and left ventricular systolic dysfunction (LVEF ≤30%)

- ① spironolactone tablets
- ② ☒ eplerenone tablets

NYHA class III/IV heart failure

- ① spironolactone tablets

Left ventricular systolic dysfunction accompanied by evidence of heart failure, both manifesting within 3-14 days of myocardial infarction

- ① ☒ eplerenone tablets

2.2.5 Osmotic diuretics

- ① ☒ mannitol infusion

2.3 Anti-arrhythmic drugs

Class 1 anti-arrhythmic (membrane stabilising drugs)

- ① ☒ flecainide tablets, injection (☒)
- ② ☒ propafenone tablets
- ② ☒☒ lidocaine injection

Class II anti-arrhythmics (beta-blockers)

- ① bisoprolol tablets
- ② ☒☒ metoprolol injection

Class III anti-arrhythmics

- ① ☒ sotalol tablets
- ② ☒ amiodarone tablets, injection (☒)

Class IV anti-arrhythmics (calcium channel blockers)

- ① verapamil tablets, injection (☒)

Other anti-arrhythmics

- ① digoxin tablets, injection (☒)
- ☒ adenosine injection

2.4 Beta-adrenoceptor blocking drugs

Heart failure

- ① bisoprolol tablets
- ② ☒ carvedilol tablets

Hypertension

- ① atenolol tablets
- ① bisoprolol tablets

Hypertension in pregnancy – refer to local guidelines

Angina

- ① atenolol tablets
- ① bisoprolol tablets

Post myocardial infarction

- ① bisoprolol tablets

Anxiety, thyrotoxicosis, essential tremor

- ① propranolol tablets

Intravenous formulations

- ☒ atenolol injection (*as per prescribing guideline ADTC 129*)
- ☒ esmolol injection
- ☒ metoprolol injection
- ☒ labetalol injection

2.5.1 Vasodilator antihypertensive drugs

- ① ☒ hydralazine tablets
- ☒☒ hydralazine injection

2.5.2 Centrally acting anti-hypertensive drugs

- ① ☒ methyl dopa tablets

2.5.4 Alpha-adrenoceptor blocking drugs

- ① doxazosin tablets

2.5.5.1 Angiotensin-converting enzyme inhibitors

- ① lisinopril tablets
- ① ramipril capsules, tablets

Prophylaxis of cardiovascular events or post myocardial infarction with LVF

- ① ramipril capsules, tablets

2.5.5.2 Angiotensin-II receptor antagonists

Heart failure or hypertension:

- ① losartan tablets
- ① candesartan tablets
- ☒ valsartan capsules (*post MI only*)

Diabetic nephropathy in type 2 diabetes mellitus:

- ① irbesartan tablets
- ① losartan tablets

① First choice within class

② Second choice within class

③ Third choice within class

☒ Hospital use

☒ Consultant initiation

☒ Specialist initiation

Neprilysin/ Angiotensin-II receptor antagonists

- ☒ sacubitril/ valsartan (Entresto®) – available in line with [SIGN 147: Management of chronic heart failure, March 2016](#)

2.5.6. Other medicines beneficial in heart failure

- ☒ dapagliflozin tablets

2.6.1 Nitrates

- ① glyceryl trinitrate sublingual spray (infusion ☒)
- ① isosorbide mononitrate tablets, mr tablets

2.6.2 Calcium-channel blockers

Hypertension

- ① amlodipine tablets

Hypertension in pregnancy – refer to local guidelines

Angina – patients not receiving a beta blocker

- ① diltiazem mr tablets, mr capsules - *modified release preparations should be prescribed by brand name*
- ① verapamil tablets, mr tablets, mr capsules

Angina – patients receiving a beta blocker

- ① amlodipine tablets

Supraventricular arrhythmias

- ① verapamil tablets, injection (☒)

Subarachnoid haemorrhage

- ① ☒☒ nimodipine tablets, infusion

Raynaud's disease

- ① nifedipine capsules

2.6.3 Other anti-anginal drugs

- ① nicorandil tablets

Intolerance or contraindication to beta-blockers and rate limiting calcium channel blockers

- ① ivabradine tablets

2.6.4 Peripheral vasodilators

Treatment should be reassessed after three months and discontinued if of no benefit.

- ① naftidrofuryl oxalate capsules

2.7 Sympathomimetics

Sympathomimetics:

- ① ☒ adrenaline injection

Inotropic sympathomimetics

- ① ☒ dobutamine infusion
- ① ☒ dopamine infusion

Vasoconstrictor sympathomimetics:

- ①☒ ephedrine injection
- ① ☒ noradrenaline acid tartrate injection

Severe orthostatic hypotension

- ① ☒ midodrine tablets (*as per SMC advice*)

2.8.1 Parenteral anticoagulants

- ① unfractionated heparin injection

Prophylaxis of DVT:

- ① dalteparin injection
- ② unfractionated heparin - *where immediate effect is needed or reversibility is appropriate or in patients with CrCl < 30 ml/min*

Unstable angina non ST and ST segment elevation myocardial infarction:

- ① fondaparinux 2.5mg prefilled syringe
- ② dalteparin injection

Treatment of Deep Vein Thrombosis and/or Pulmonary Embolism

- ① dalteparin injection
- ② unfractionated heparin - *where immediate effect is needed or reversibility is appropriate or in patients with CrCl < 30 ml/min*

Other parenteral anticoagulants

- ① ☒☒ danaparoid injection
- ② ☒☒ argatroban injection
- ☒☒ epoprostenol injection

2.8.2 Oral anticoagulants

Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation

Refer to local guidelines on the choice of oral anticoagulants in patients with non-valvular atrial fibrillation (ADTC 290)

- ① edoxaban tablets
- ① warfarin tablets

Treatment of Deep Vein Thrombosis and/or Pulmonary Embolism

Refer to local guidelines on the choice of oral anticoagulants for the treatment of non-pregnant adults with suspected Deep Vein Thrombosis and/or Pulmonary Embolism (ADTC 302) or the ICP for IV Drug User with Suspected DVT (excluding pregnant patients) (ADTC 109)

- ① apixaban tablets
- ① warfarin tablets

Prophylaxis of venous thromboembolism in orthopaedics

- ① rivaroxaban tablets

Use in combination with aspirin in Coronary Artery Disease

▣ rivaroxaban 2.5mg tablet (Xarelto®) – restricted to patients with stable coronary artery disease that do not require dual antiplatelet therapy (SMC 2128)

Other indications

- ① warfarin tablets

2.8.3 Protamine sulphate

- ① ▣ ▨ protamine sulphate injection

2.8.4 Reversal of anticoagulation

- ▣ ▨ andexanet alfa infusion – as per local guideline
- ▣ ▨ idarucizumab (Praxbind®) injection/infusion

2.9 Antiplatelet drugs

Refer to NHS Ayrshire & Arran anti-platelet guidelines (ADTC 17) – these provide additional information on place in therapy

- Aspirin dispersible tablets
- clopidogrel tablets
- dipyridamole mr capsules – patients after ischaemic stroke or TIA unable to tolerate clopidogrel
- ▣ ticagrelor tablets

Treatment of high risk unstable coronary syndrome

- ▣ ▨ tirofiban infusion

2.10.2 Fibrinolytic drugs

Acute myocardial infarction

- ① ▣ ▨ tenecteplase injection

Acute ischaemic stroke

- ① ▣ ▨ alteplase injection

Massive pulmonary embolism

- ① ▣ ▨ alteplase injection
- ▣ streptokinase injection

2.11 Antifibrinolytic drugs and haemostatics

- ① tranexamic acid tablets, injection (▣)

2.12 Lipid-regulating drugs

(a) statins

- ① simvastatin tablets
- ② atorvastatin tablets
- Pravastatin tablets

(b) bile acid sequestrants

- ① colestyramine sachets

(c) fibrates

- ① fenofibrate tablets

d) others

- ▣ alirocumab injection (case by case form requires to be completed until protocol available)
- ▣ evolocumab injection (case by case form requires to be completed until protocol available)
- ▣ inclisiran injection (Leqvio®) (case by case form requires to be completed until protocol available)
- ▣ bempedoic acid tablets (Nilemdo®) – initiation by Lipid clinic only
- ▣ bempedoic acid/ ezetimibe tablets (Nustendi®) – initiation by Lipid clinic only

2.13 Local sclerosants

- ① ▣ ▨ sodium tetradecyl sulphate injection

3: RESPIRATORY SYSTEM

Inhalers should be prescribed as per local asthma (adult) or COPD guidelines

3.1.1 Adrenoceptor agonists (Sympathomimetics)

(a) short-acting beta2-agonist bronchodilators (SABA)

Inhaler preparations

With the **exception** of salbutamol Metered Dose Inhaler (MDI), please prescribe these inhalers by brand name

- ① salbutamol MDI
- ② Easyhaler® salbutamol 100 micrograms

Other formulations

- ① salbutamol nebuliser solution, injection
- ② ☒ terbutaline nebuliser solution, injection

(b) long-acting beta2-agonist bronchodilators (LABA)

Prescribe these inhalers by brand name.

- ① formoterol Easyhaler®
- ② formoterol MDI (Atimos Modulite®)

3.1.2 Antimuscarinic bronchodilators

Long acting antimuscarinic (LAMA) inhaler preparations – asthma (adults)

Prescribe these inhalers by brand name.

- ① ☒ tiotropium (Spiriva® Respimat®)

Long acting antimuscarinic (LAMA) inhaler preparations – COPD

Prescribe these inhalers by brand name. Choice determined by inhaler technique

- ① tiotropium (Spiriva® Respimat®)
- ① umeclidinium (Incruse® Ellipta®)

Other formulations

- ① ipratropium bromide nebuliser solution – when used long term, this must be administered via a mouthpiece

3.1.3 Theophylline

- ① theophylline (Uniphyllin Continus®) tablets
- ① ☒ aminophylline injection

3.1.4 Compound bronchodilator preparations

none

Combination long acting muscarinic antagonists and long acting beta 2 agonist (LAMA/ LABA combination)

Prescribe these inhalers by brand name. Choice determined by inhaler technique

- ① umeclidinium / vilanterol (Anoro® Ellipta®)
- ① olodaterol/ tiotropium (Spiolto® Respimat®)

3.1.5 Nebuliser diluent

- ① sodium chloride nebuliser solution

3.2 Corticosteroids

(a) inhaled corticosteroids (ICS)

Prescribe these inhalers by brand name. Choice determined by inhaler technique

MDI

- ① beclometasone (Soprobec®) MDI

DPI

- ① Easyhaler® beclometasone
- ② Easyhaler® budesonide

(b) other corticosteroids

Oral:

- ① prednisolone tablets 1mg, 5mg, 5mg/5ml oral solution, soluble tablets

Intravenous injection:

- ① hydrocortisone sodium succinate injection

(c) combination products (ICS/ LABA combination inhalers)

Asthma (adults)

Prescribe these inhalers by brand name. Choice determined by inhaler technique

Asthma (adults)

Low Dose ICS/LABA combinations

MDI

- ① beclometasone/formoterol (Fostair®) 100/6 *

DPI

- ① budesonide/formoterol (Fobumix® Easyhaler®) 160/4.5 *

Medium/High Dose ICS/LABA combinations

MDI

- ① fluticasone/salmeterol (AirFluSal®) MDI 125/25, ☒ 250/25
- ② beclometasone/formoterol (Fostair®) 100/6*, ☒ 200/6

DPI

- ① budesonide/formoterol (Fobumix® Easyhaler®) 160/4.5*, ☒ 320/9
- ② fluticasone/vilanterol (Relvar® Ellipta®) 92/22**, ☒ 184/22

*Inhalers licensed for MART use

**Relvar® Ellipta®) 92/22 is low/medium dose ICS/LABA combination

① First choice within class

② Second choice within class

③ Third choice within class

☒ Hospital use

☒ Consultant initiation

☒ Specialist initiation

COPD

Prescribe these inhalers by brand name.
Choice determined by inhaler technique

- ① fluticasone/ vilanterol (*Relvar® Ellipta®*) 92/22
- ① Beclometasone/ formoterol (*Fostair®*) 100/6 MDI

d) combination products (ICS/ LABA/LAMA)

COPD

Prescribe these inhalers by brand name.
Choice determined by inhaler technique

- ① Beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium metered dose inhaler (*Trimbow®*)
- ① Fluticasone furoate, umeclidinium, vilanterol (as trifenatate) inhalation powder (*Trelegy® Ellipta®*)

Asthma

Prescribe these inhalers by brand name.

- ☒ ① Beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium metered dose inhaler (*Trimbow®*)

3.3.1 Cromoglicate and related therapy

none recommended

3.3.2 Leukotriene receptor antagonists

- ① montelukast tablets

3.4.1 Antihistamines

Non-sedating antihistamines

- ① cetirizine tablets, oral solution
- ② loratadine tablets, oral solution

Sedating antihistamines

- ① chlorphenamine tablets, syrup
- ② hydroxyzine tablets (*Do not prescribe hydroxyzine to people with a prolonged QT interval or risk factors for QT interval prolongation – [MHRA warning](#)*)
- ② promethazine tablets, oral solution (*alternative in patients where potential QT prolongation with hydroxyzine may be of concern*)

3.4.2 Allergen immunotherapy

IgE (immunoglobulin E) mediated asthma

- ☒ ☒ ① omalizumab injection (*as per local protocol*)

Severe refractory eosinophilic asthma

- ☒ ☒ ① mepolizumab injection (*as per local protocol*)
- ☒ ☒ ② benralizumab injection (*case by case form requires to be completed until protocol available*)

3.4.3 Allergic emergencies

Anaphylaxis

- adrenaline injection (includes EpiPen®)
- chlorphenamine injection
- hydrocortisone injection

Angioedema

- ☒ C1 esterase inhibitor (*Berinert®*) injection – *tertiary centre clinician initiation*

3.5.1 Respiratory stimulants

- ☒ ☒ caffeine citrate (*Peyona®*) oral solution

3.5.2 Pulmonary surfactants

- ☒ ☒ poractant alfa endotracheopulmonary instillation suspension

3.6 Oxygen

oxygen

3.7 Mucolytics

- ① acetylcysteine 600 mg effervescent tablets (*NACSYS®*) (*for COPD only – prescribe by brand name*)
- ☒ dornase alfa nebuliser solution (*for cystic fibrosis only*)
- ☒ mannitol inhalation powder
- ☒ hypertonic sodium chloride

3.8 Aromatic inhalations

none recommended

3.9 Cough preparations

none recommended

3.10 Systemic nasal decongestants

Pseudoephedrine tablets

3.11 Antifibrotics

- ☒ pirfenidone capsules, tablets (*as per local guideline*)
- ☒ nintedanib capsules (*Ofev®*) (*as per local guideline*)

4: CENTRAL NERVOUS SYSTEM

4.1 Hypnotics and anxiolytics

4.1.1 Hypnotics

- ① no treatment
- ① zopiclone
- ② temazepam

Chloral and derivatives

Clomethiazole (*not for alcohol withdrawal*)

4.1.2 Anxiolytics

chlordiazepoxide (*alcohol withdrawal*)
diazepam
lorazepam (injection)
propranolol

4.2.1 Antipsychotic drugs

First generation antipsychotic drugs

- ① haloperidol tablets, liquid, injection
- ② chlorpromazine tablets, liquid (*except the elderly*)
- zuclopenthixol acetate injection (*Clopixol Acuphase®*)

Second generation antipsychotic drugs

- ① quetiapine tablets, modified release tablets
- ② risperidone tablets, orodispersible tablets, liquid
- ② aripiprazole tablets, liquid
- ③ olanzapine tablets, orodispersible tablets (injection)
- clozapine tablets, liquid (*use in conjunction with local protocols*)
- amisulpride tablets, liquid
- lurasidone tablets

Quetiapine first choice where depot injection is not part of the treatment plan.

Risperidone and aripiprazole second choice, but first choice if depot injection included in the treatment plan.

Choices 1,2,3 also indicated for hospital inpatients for treatment of acute mania.

4.2.2 Antipsychotic depot injections

First generation depot injections

- ① zuclopenthixol decanoate
- ② flupentixol decanoate
- ③ haloperidol decanoate

Second generation depot injections

- ① paliperidone palmitate (*Xeplion®, Trevicta®*)
- ② aripiprazole (*Abilify Maintena®*)
- ③ risperidone (*Risperdal Consta®*)

4.2.3 Drugs for mania and hypomania

- ① lithium tablets, liquid (*Priadel®*)
- ② valproic acid (as semisodium valproate) tablets (*Depakote®*)
- ③ carbamazepine tablets, liquid
- ③ lamotrigine tablets, dispersible tablets

- *Depakote® should not be used in female children, in female adolescents, in women of childbearing potential and pregnant women unless alternative treatments are ineffective or not tolerated because of its high teratogenic potential and risk of developmental disorders in infants exposed in utero to valproate*
- *Lamotrigine is indicated for prevention of depressive episodes in patients with bipolar I disorder who experience predominantly depressive episodes*

4.3 Antidepressant drugs

4.3.1 Tricyclic and related antidepressant drugs

- amitriptyline
- clomipramine
- imipramine
- lofepramine
- trazodone

4.3.2 Monoamine oxidase inhibitors (MAOIs)

- moclobemide
- phenelzine

4.3.3. Selective serotonin re-uptake inhibitors (SSRIs)

- ① fluoxetine (*tablet, dispersible tablet liquid*)
- citalopram (*QTc prolongation risk, including antipsychotics (but also with non-psychotropic drugs). To be used with caution and ECG monitoring advisable where additional psychotropic commenced or cardiac history*)
- sertraline

Elderly Mental Health

- ① sertraline

Generalised anxiety disorder

Escitalopram

4.3.4 Other antidepressant drugs

- duloxetine (*Cymbalta®*)
- mirtazapine
- venlafaxine (*BP monitoring required at baseline, commencement and any dose increase*)
- vortioxetine tablet as per SMC restrictions

4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder

Special Prescribing Agreements for the following medicines are under development:

- ☑ atomoxetine
- ☑ dexamphetamine
- ☑ guanfacine
- ☑ lisdexamfetamine
- ☑ methylphenidate

4.5 Drugs used in the treatment of obesity diet and lifestyle changes orlistat

4.6 Drugs used in nausea and vertigo (a) antihistamines

cyclizine
promethazine

b) phenothiazine and related drugs

levomepromazine
prochlorperazine

c) domperidone and metoclopramide

metoclopramide
domperidone

d) 5HT₃ receptor antagonists

① ondansetron (☑ orodispersible film)
② granisetron (☑ patch)

e) Neurokinin receptor antagonists

③ aprepitant
fosaprepitant

f) Hyoscine

hyoscine hydrobromide

g) Other drugs for Ménière's disease

betahistine

4.7 Analgesics

Also refer to section 15.1.4.2 Peri-operative analgesics

Paracetamol tablets

Compound analgesic preparations

co-codamol 8/500 tablets
co-codamol 30/500 tablets

4.7.2 Opioid analgesics

Refer to local pain guidelines for further advice

buprenorphine transdermal patch (Buteo®) – for use in patients over 65 years of age only. Prescribe by brand name to avoid confusion
codeine phosphate tablets
diamorphine injection

dihydrocodeine tablets (injection ☑)
Fentanyl patches
☑ fentanyl sublingual (Abstral®) tablets
☑ Fentanyl injection
☑ hydromorphone capsules, mr capsules
☑ methadone liquid
morphine tablets, mr capsules, injection
Zomorph® -recommended brand of oral modified release morphine
☑ Oxycodone capsules, mr tablets
Oxypro® - recommended brand of oral modified release Oxycodone
Shortec® recommended brand of oral immediate release Oxycodone
tramadol (injection ☑, excludes modified release, suppository and oral drop preparations)

4.7.3 Neuropathic pain

Refer to local persistent pain guideline

Amitriptyline tablets

- ② duloxetine capsules – diabetic neuropathy
- ② gabapentin capsules
- ③ pregabalin capsules

4.7.4 Antimigraine drugs

4.7.4.1 Treatment of acute migraine

(a) mild to moderate migraine

- ① Aspirin (900mg) OR
- ① Ibuprofen (400mg) OR
- ① Paracetamol (1000mg)

(b) severe migraine

- ① sumatriptan tablets
- ② almotriptan tablets
- ② zolmitriptan tablets
- ③ zolmitriptan nasal spray - where oral not appropriate
- ③ sumatriptan injection - where oral/nasal not appropriate

4.7.4.2 Prophylaxis of migraine (adults)

- ① propranolol capsules
- ② topiramate tablets
- ☑ Botulinum toxin A (Botox®) - Restricted to use as per approved protocol
- ☑ Erenumab prefilled pen or syringe - Restricted to use as per approved protocol

4.7.4.3 Treatment of cluster headache (adults)

- ① Sumatriptan subcutaneous Injection

① First choice within class

② Second choice within class

③ Third choice within class

☑ Hospital use

☑ Consultant initiation

☑ Specialist initiation

4.8 Antiepileptic drugs

4.8.1 Control of the epilepsies

carbamazepine
lamotrigine
 sodium valproate (injection
oxcarbazepine

second choice agents on specialist recommendation

4.8.2 Drugs used in status epilepticus

diazepam rectal solution
 lorazepam injection
 phenytoin injection

4.8.3 Febrile convulsions

diazepam
paracetamol

4.9 Drugs used in parkinsonism and related disorders

4.9.1 Dopaminergic drugs used in Parkinson's Disease

(a) dopamine receptor-agonists

apomorphine
bromocriptine
cabergoline
pramipexole
ropinirole
rotigotine (not first line)

(b) levodopa

co-beneldopa (Madopar®)
co-careldopa (Sinemet®)
 co-carelopa (Duodopa®) intestinal gel
(*case by case form requires to be completed until protocol available*)

(c) monoamine oxidase B inhibitors

selegiline

(d) Catechol-o-methyltransferase inhibitors

entacapone
levodopa/ carbidopa/ entacapone (use where compliance issues on taking individual components)

(e) Amantadine

amantadine

4.9.2 Antimuscarinic drugs used in parkinsonism

orphenadrine
procyclidine (injection
trihexyphenidyl

4.9.3 Drugs used in essential tremor, chorea, tics, and related disorders

chlorpromazine
haloperidol
propranolol
tetrabenazine

Torsion dystonias and other involuntary movements

botulinum toxin A (*prescribe by brand name*)

4.10 Drugs used in substance dependence

Alcohol dependence

a) alcohol withdrawal

Use in conjunction with local protocols

Outpatients and general practice

① chlordiazepoxide capsules

In-patients

① diazepam tablets
② chlordiazepoxide capsules
 diazepam injection (emulsion) 5mg/mL
(Diazemuls®)

b) maintenance of abstinence and relapse prevention

① acamprosate tablets
① Naltrexone tablets
② disulfiram tablets

Opioid dependence

a) acute opioid withdrawal symptoms

① symptomatic relief
① lofexidine tablets

(b) Management of opioid dependence

① methadone 1mg/ml oral solution
② buprenorphine / naloxone (Suboxone®) tablet, sublingual film (*as per local guideline*)
② buprenorphine oral lyophilisate (Espranor®) (*as per local guideline*)
② buprenorphine tablets (*as per local guideline for patients not requiring supervised administration*)
③ buprenorphine prolonged released solution for injection (Buvidal®)

(c) Maintenance of abstinence and relapse prevention

① naltrexone tablets

① First choice within class

② Second choice within class

③ Third choice within class

Hospital use

Consultant initiation

Specialist initiation

(d) Opioid overdose prevention

- ① naloxone injection (*Prenoxad*®)
- ② naloxone hydrochloride dihydrate nasal spray (*Nyxoid*®)

Nicotine dependence

Use as per local guideline

First line option

- ① smoking cessation support **AND**
Nicotinell® 7mg, 14mg, 21mg patches

Where dual therapy required:

- ① smoking cessation support **AND**
Nicotinell® 7mg, 14mg, 21mg patches **AND**
Nicotinell® 1mg, 2mg lozenges **OR** Nicotinell®
2mg, 4mg gum

- ② smoking cessation support **AND**
Nicotinell® 7mg, 14mg, 21mg patches **AND**
Nicorette® inhalator **OR** mouth spray

- ① varenicline
- ② bupropion

4.11 Drugs for dementia

For consultant initiation and treatment as per NICE TAG 217

- donepezil
- galantamine
- rivastigmine
- memantine

5: INFECTIONS

This section contains the medicines included in the NHS Ayrshire & Arran antimicrobial guidelines, listed according to BNF classification. The relevant antimicrobial guidelines **must** be referred to for further information on their place in therapy and any restrictions on use. A full list of antimicrobial guidelines for primary and secondary care patients can be found on the NHS Ayrshire & Arran intranet ([AthenA](#)) or via [Antimicrobial Companion](#)

In addition, some antibiotics are restricted to use for specific clinical indications which are detailed in the Protected Antimicrobial list (available on antimicrobial site on Athena). This list contains the approved indications for the use of protected antimicrobials in NHS Ayrshire and Arran by prescribers who are not Infection Specialists (Consultants in Infectious diseases or Consultant Microbiologists), either for empirical therapy or targeted at specific conditions / organisms. All use is subject to licensing and any SMC restrictions.

Further advice on treatment can be sought from the Consultant Microbiologists or the Antimicrobial pharmacists

☒ indicates that should be on recommendations of Specialist Consultant such as Microbiology or Infectious Diseases

5.1 Antibacterial drugs

5.1.1 Penicillins

Benzylpenicillin and phenoxymethylpenicillin

benzylpenicillin injection
phenoxymethylpenicillin tablets

Penicillinase-resistant penicillins

Flucloxacillin capsules, injection
☒ temocillin injection

Broad-spectrum penicillins

Amoxicillin capsules, injection
co-amoxiclav tablets, injection

Antipseudomonal penicillins

piperacillin with tazobactam injection

5.1.2 Cephalosporins, carbapenems, and other beta-lactams

Cephalosporins

cefuroxime injection
ceftriaxone injection
cephalexin tablets, capsules
☒ ceftazidime injection

Carbapenems

☒ meropenem injection

5.1.3 Tetracyclines

Management of acne refer to section 13.6.2
doxycycline tablets, capsules
☒ tigecycline infusion

5.1.4 Aminoglycosides

☒ amikacin injection
☒ dalbavancin infusion
gentamicin injection
☒ tobramycin nebuliser solution

5.1.5 Macrolides

azithromycin capsules, tablets
☒ azithromycin injection
clarithromycin tablets, injection
erythromycin tablets

5.1.6 Clindamycin

☒ clindamycin tablets, injection

5.1.7 Some other antibacterials

☒ chloramphenicol injection
☒ daptomycin injection
☒ fidaxomicin tablets
☒ fosfomycin infusion
fosfomycin granules
☒ linezolid tablets, injection
☒ rifaximin 550mg tablets (*Targaxan*®)
sodium fusidate tablets, injection
teicoplanin injection
vancomycin capsules, infusion

5.1.8 Sulfonamides and trimethoprim

trimethoprim tablets
☒ co-trimoxazole tablets, injection

5.1.9 Antituberculosis drugs

Seek specialist advice for the management of tuberculosis

5.1.10 Antileprotic drugs

☒ dapsone tablets

5.1.11 Metronidazole and tinidazole

Metronidazole tablets, infusion

5.1.12 Quinolones

Due to the risk of severe, disabling and potentially permanent adverse events, new restrictions apply to the prescribing of fluoroquinolones. Please see the [MHRA](#) advice (November 2018) and additional [MHRA](#) advice (March 2019) for more details.
ciprofloxacin tablets, infusion (IV on PL)
levofloxacin tablets, infusion
☒ levofloxacin nebuliser solution

① First choice within class

② Second choice within class

③ Third choice within class

☒ Hospital use

☒ Consultant initiation

☒ Specialist initiation

5.1.13 Lower Urinary-tract infections

Women (uncomplicated lower UI)

Refer to local guidelines available on
Microguide/ Athena

Men (uncomplicated lower UTI)

Refer to local guidelines available on
Microguide/ Athena

Pregnancy (uncomplicated lower UTI)

Refer to local guidelines available on
Microguide/ Athena

5.2 Antifungal drugs

Triazole antifungals

Fluconazole capsules, infusion

☑¹ Isavuconazole infusion

Itraconazole capsules, infusion

☑ posaconazole tablets

☑ posaconazole infusion

☑ voriconazole tablets, infusion

Imidazole antifungals

Also see section 7.2.2 and 13.10.2

Polyene antifungals

☑ liposomal amphotericin infusion
(AmBisome®)

Echinocandin antifungals

☑ caspofungin infusion
☑ micafungin infusion

Other antifungals

terbinafine tablets, cream

5.3 Antiviral drugs

5.3.1 HIV infection

Refer to NHS Ayrshire & Arran
guidelines for the treatment of HIV in
adults for the treatment choices -
specialist consultant initiation only

☑ emtricitabine/ tenofovir disoproxil tablets
(Truvada®)- use in combination with safer sex
practices for pre-exposure prophylaxis (PrEP)
to reduce the risk of sexually acquired HIV-1
infection in adults at high risk is restricted to
specialist use only by consultants in Infectious
Diseases

5.3.2 Herpesvirus infections

Herpes simplex and varicella-zoster infection

aciclovir tablets, cream

☑ aciclovir injection

Cytomegalovirus infection

☑ ganciclovir infusion

☑ valganciclovir tablets

5.3.3 Viral hepatitis

For Hepatitis C – refer to [NHS Scotland
Clinical Guidelines for the treatment of HCV in
adults](#)

5.3.4 Influenza

For initiation as per national guidance

oseltamivir capsules

zanamivir inhalation power

☑ zanamivir infusion

5.4 Antiprotozoal drugs – seek specialist advice

5.5 Anthelmintics – seek specialist advice

① First choice within class

② Second choice within class

③ Third choice within class

☑ Hospital use

☑ Consultant initiation

☑ Specialist initiation

6: ENDOCRINE SYSTEM

6.1 Drugs used in diabetes

6.1.1 Insulins

Insulin should be initiated on specialist advice only. Choice depends on the particular needs of the individual patient, taking into account lifestyle, age, preference and capabilities. Type of insulin, device and needle size should be specified. Care should be taken to write the **brand name** in full.

Insulin preparations currently under review, and so the following is not a complete list

Short acting insulins

- soluble insulin 100units/ml injection (Actrapid®)
- Insulin aspart 100 units/mL solution for injection (Fiasp®)
- insulin aspart 100 units/mL solution for injection (NovoRapid®)
- insulin 100 units/ml solution for injection (Humalog®)

Insulin glargine

- Insulin glargine 100 units/ml (Abasaglar®)
- Insulin glargine 300 units/ml (Toujeo®)
- Insulin degludec (Tresiba®) as per protocol once available (under development)
Note: SMC approved for use in adults only

6.1.3 Insulin Pen needles

- Omnican® 32G fine pen needles
- BD Viva® pen needles – alternative in patients using Eli Lilly pen devices

6.1.2 Antidiabetic drugs

Refer to [SIGN 154](#) on the pharmacological management of type 2 diabetes

Biguanides

- metformin tablet
- metformin mr tablet

Sulphonylureas

- gliclazide tablets
- glimepiride tablets

Other antidiabetic drugs

(i) DPP-4 inhibitors

This class of medicines are not considered the most cost-effective choice when used as first-line therapy, and even when used as 2nd or 3rd line, they may only result in a modest reduction of HbA1c. Patients initiated on these agents should be reviewed at 6 months and treatment should only continue if the patient has had a beneficial metabolic response (a reduction of at least 0.5% (5.5mmol/mol) in HbA1c)

- alogliptin tablets (includes alogliptin/metformin (Vipdomet®) tablets for those with compliance issues)
- sitagliptin tablets (includes sitagliptin/metformin tablet (Janumet®) for those with compliance issues)

(ii) glitazones (thiazolidinediones)

- pioglitazone tablets

iii) glucagon like peptide (GLP-1) agonists

Daily preparation

- exenatide injection
- liraglutide injection (1.8mg dose excluded)

NB: Liraglutide (Saxenda® brand) is excluded from the formulary, which is only licensed as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults

Weekly preparation

- semaglutide injection
- dulaglutide injection

iv) sodium-glucose co-transporter 2 (SGLT2) inhibitor

- SGLT-2 inhibitors are to be used with caution in cardiovascular conditions due to increased risk of volume depletion. Caution must be exercised when using diuretics concomitantly. Hypovolaemia requires correction before initiation with an SGLT2 inhibitor.
- SGLT2 inhibitor therapy should be temporarily discontinued in conditions that may lead to fluid loss e.g. GI illness, in particular those on concomitant diuretic therapy
- MHRA Drug Safety Update: [SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis, April 2016](#)
- MHRA Drug Safety Update: [SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation \(mainly toes\), March 2017](#)

- empagliflozin tablets (includes Synjardy® (includes Synjardy® (empagliflozin/ metformin for those with compliance issues))
- dapagliflozin tablets (includes Xigduo® (dapagliflozin/ metformin) for those with compliance issues)

dapagliflozin tablets- in adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI $\geq 27\text{kg/m}^2$, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy

Diabetic kidney disease

- canagliflozin tablets

6.1.4 Treatment of hypoglycaemia

Choice of treatment depends on the clinical situation and includes:

- glucose (oral)
- glucagon injection
- glucose infusion 20%

6.1.6 Diagnostic and monitoring devices for diabetes mellitus

Blood Glucose Monitoring meters recommended within the community setting:

Adult patient group	Meter	Test strips
Patients undertaking dual glucose and ketone testing (<i>type 1 and ketosis prone type 2 diabetes patients</i>)	① 4SURE Smart Duo	4SURE blood glucose test strips 4SURE β-ketone test strips
Patients undertaking carbohydrate counting	① FreeStyle InsuLinx	Freestyle Lite test strip
	② Accu-Chek Aviva Expert	Accu-Chek Aviva blood glucose test strips
Type 2 diabetes	① TRUE METRIX	TRUE METRIX blood glucose test strips
	② TEE2	Tee2 blood glucose test strips

Specialist initiation		
Adult patient group	Meter	Test strips
Medtronic insulin 640 pumps	① CONTOUR NEXT LINK	CONTOUR NEXT LINK test strips
Medtronic insulin 780 pumps	① Accu-Chek Guide Link	Accu-Chek Guide test strips
Accu-Chek Combo insulin pump	① Accu-Chek Aviva Expert	Accu-Chek Aviva blood glucose test strips
Accu-Chek Insight insulin pump	① Accu-Chek Aviva Expert	Accu-Chek Aviva blood glucose test strips
Patients with visual impairment (<i>type 1 or 2 diabetes</i>)	① GlucoRx Nexus Voice meter	GlucoRx Nexus Test Strips
Patients unable to self titrate insulin doses (<i>type 1 diabetes and ketosis prone type 2 diabetes patients</i>)	① FreeStyle Libre handset	FreeStyle Optium blood glucose test strips
Patients unable to handle individual strips and lancets (<i>type 1 or 2 diabetes</i>)	① Accu-Chek Mobile	Accu-Chek Mobile test cassette

① First choice within class

② Second choice within class

③ Third choice within class

🏥 Hospital use

👤 Consultant initiation

🏥 Specialist initiation

6.2 Thyroid and antithyroid drugs

6.2.1 Thyroid hormones

levothyroxine

☒ liothyronine (injection ☒)

6.2.2 Anti-thyroid drugs

① carbimazole

propylthiouracil

☒ ☒ aqueous iodine

6.3 Corticosteroids

6.3.1 Replacement therapy

Hydrocortisone (*excludes modified-release tablets*)

fludrocortisone

6.3.2 Glucocorticoid therapy

betamethasone

dexamethasone 2mg soluble tablets,

2mg tablets

hydrocortisone

☒ methylprednisolone

prednisolone tablets (*excludes 25mg strength*), 5mg/5ml oral solution, soluble tablets

6.4 Sex hormones

6.4.1 Female sex hormones and their modulators

6.4.1.1 Oestrogens and HRT

Refer to local HRT guidelines for product choices

① oral preparations

② transdermal patches

tibolone

6.4.1.2 Progestogens and progesterone receptor modulators

norethisterone

progesterone

Progesterone receptor modulators

☒ ulipristal acetate (*Esmya*®)

Notes on use regarding *Esmya*® (Feb 2018)

- The European Medicines Agency (EMA) is currently reviewing the benefits of ulipristal acetate (*Esmya*®) when used for uterine fibroids following reports of serious liver injury. Whilst this review is ongoing do not initiate or re-start treatment in any patient.
- Further information, including guidance for patients, is available from the [MHRA website](#)

6.4.2 Male sex hormones and antagonists

☒ testosterone (*Nebido*®) injection

☒ testosterone gel

☒ testosterone tablets

Anti-androgens

☒ cyproterone

Dutasteride and finasteride

① finasteride

② dutasteride

dutasteride and tamsulosin (*Combodart*®)

6.5 Hypothalamic and pituitary hormones and anti-oestrogens

6.5.1 Hypothalamic and anterior pituitary hormones and anti-oestrogens

☒ clomifene

Anterior pituitary hormones

Corticotrophins for testing

☒ tetracosactide

Gonadotrophins

☒ ☒ chorionic gonadotrophin injection

☒ ☒ follitropin alfa and beta injection

☒ ☒ choriogonadotropin alfa pre-filled (*Ovitrelle*®) syringe

Growth hormone

☒ Somatropin injection (*recommendations of specialist consultant at Yorkhill Hospital – centre provides a shared care protocol*)

Hypothalamic hormones

☒ gonadorelin

6.5.2 Posterior pituitary hormones and antagonists

(a) diabetes insipidus

desmopressin *nasal spray*

desmopressin *tablets*

☒ desmopressin injection

(b) antidiuretic hormone antagonists

☒ demeclocycline

(c) oesophageal varices

☒ ☒ terlipressin

d) idiopathic nocturnal polyuria

☒ desmopressin 25 microgram, 50

microgram oral lyophilisate (*Noqdirna*®) – *use in patients aged 65 years and over only*

6.6 Drugs affecting bone metabolism

6.6.1 Calcitonin and parathyroid hormones

☒ calcitonin (salmon)

① First choice within class

② Second choice within class

③ Third choice within class

☒ Hospital use

☒ Consultant initiation

☒ Specialist initiation

6.6.2 Bisphosphonates and other drugs affecting bone metabolism

- ① alendronic acid tablets, effervescent tablets
- ② risedronate sodium tablets
- ☒ denosumab injection (*Xgeva*®), as per West of Scotland Cancer Network protocol
- ☒ disodium etidronate
- ☒ disodium pamidronate
- ☒ ibandronic acid tablets
- ☒ ☒ ibandronic acid injection
- raloxifene
- sodium clodronate
- strontium ranelate
- ☒ ☒ zoledronic acid infusion

6.7 Other endocrine drugs

6.7.1 Bromocriptine and other dopaminergic drugs

- bromocriptine
- ☒ cabergoline

6.7.2 Drugs affecting gonadotrophins

Gonadorelin analogues

- ☒ buserelin nasal spray
- ☒ goserelin injection
- ☒ triptorelin (*Decapeptyl SR*®) injection

6.7.3 Metyrapone

- ☒ metyrapone

7: OBSTETRICS, GYNAECOLOGY & URINARY- TRACT DISORDERS

7.1 Drugs used in obstetrics

7.1.1 Prostaglandins and oxytocics

- ☒ carboprost
- ☒ dinoprostone (*excludes 10mg vaginal delivery system*)
- ☒ ergometrine
- ☒ gemeprost
- ☒ oxytocin
- ☒ *ergometrine/ oxytocin (Syntometrine®)*

7.1.1.1 Drugs affecting the ductus arteriosus

Maintenance of patency

- ☒ alprostadil

Closure of ductus arteriosus

- ☒ indometacin injection

7.1.2 Mifepristone

- ☒ ☒ mifepristone
- ☒ ☒ mifepristone/ misoprostol (*Megdabon®*) combipak

7.1.3 Myometrial relaxants

- ☒ salbutamol injection

7.2 Treatment of vaginal and vulval conditions

7.2.1 Preparations for vaginal changes

- ① Ovestin®
- ☒ Ospemifene tablets (Senshio®)

7.2.2 Vaginal and vulval infections

Preparations for vaginal and vulval candidiasis

- ① clotrimazole
- ② econazole

Other infections

povidone iodine

Bacterial vaginosis

Refer to [primary care empirical antibiotic guidelines](#) for further information and treatment choices

- ② dequalinium chloride vaginal tablets – *for patients who fail initial treatment options.*

7.3 Contraceptives

Refer to *West of Scotland Sexual Health MCN clinical guidelines*

7.3.1 Combined hormonal contraceptives

Combined Oral Contraceptives (COCs)

7.3.1.1 Monophasic low strength (21-day preparations)

(NB: low strength monophasic COCs are considered **second line agents** as breakthrough bleeding is more common than with standard strength monophasic COCs)

- ① Gedarel 20/150® (*ethinylestradiol 20mcg with desogestrel 150mcg*) tablet

7.3.1.2 Monophasic standard strength (21-day preparations)

(NB: Monophasic standard strength COCs are considered **first line agents**)

- ① Levest® (*ethinylestradiol 30mcg with levonorgestrel 150mcg*) tablet
- ① Rigevidon® (*ethinylestradiol 30mcg with levonorgestrel 150mcg*) tablet
- ② Brevinor® (*ethinylestradiol 35mcg with norethisterone 500mcg*) tablet

7.3.1.3 Monophasic standard strength (28-day 'Every day' preparations)

- ① Microgynon 30 ED® (*ethinylestradiol 30mcg with levonorgestrel 150mcg*) tablet

Vaginal (low strength)

- ☒ NuvaRing® (*ethinylestradiol with etonogestrel*)

7.3.2 Oral progestogen-only contraceptives

- ① Noriday® (*norethisterone 350 mcg*) tablet
- ① Norgeston® (*levonorgestrel 30 mcg*) tablet
- ② Cerelle® (*desogestrel 75mcg*) tablet

7.3.2.2 Parenteral progestogen- only contraceptives

Refer to *West of Scotland Sexual Health MCN clinical guidelines*

- ① medroxyprogesterone acetate (Depo-Provera®) intramuscular injection
- ① medroxyprogesterone acetate (Sayana® Press) subcutaneous depot injection (*Sexual Health clinic or Ayrshire Maternity Unit Day ward initiation for women undertaking self-administration, as per local standard operating procedures*)

etonogestrel (Nexplanon®) implant

① First choice within class

② Second choice within class

③ Third choice within class

☒ Hospital use

☒ Consultant initiation

☒ Specialist initiation

7.3.2.3 Intra-uterine progestogen-only device

Prescribe by brand name to avoid confusion

- ① levonorgestrel (Levosert®) intrauterine system (6 year system)
- ② levonorgestrel (Mirena®) intrauterine system (5 year system)
- ③ levonorgestrel (Jaydess®) intrauterine delivery system (3 year system)
- ④ levonorgestrel (Kyleena®) intrauterine delivery system (5 year system)

7.3.4 Contraceptive devices

Refer to West of Scotland Sexual Health MCN clinical guidelines

7.3.5 Emergency contraception

Copper IUD is more effective than any oral method and should be considered as an option

levonorgestrel 1500 mcg tablets
(patients presenting within 72 hours of unprotected sexual intercourse)

ulipristal (EllaOne®) tablets
(patients presenting 72 to 120 hours after unprotected sexual intercourse)

7.4 Drugs for genito-urinary disorders

7.4.1 Drugs for urinary retention

a) alpha-blockers

- ① tamsulosin
- alfuzosin (① in younger men)
- ② doxazosin

b) 5 α -reductase inhibitors

- ① finasteride
- ② dutasteride

c) combination products

dutasteride plus tamsulosin (Combodart®)
solifenacin plus tamsulosin (Vesomni®)

7.4.2 Drugs for urinary frequency, enuresis and incontinence

- ① tolterodine immediate release tablets
- ② solifenacin tablets
- ③ mirabegron - should be restricted to third line use in patients who have not responded to treatment with two different antimuscarinics or in whom antimuscarinics are contraindicated.
It may also be considered as a first line option where there is concern that patients have a high anticholinergic load. Further information about anticholinergic load can be read in the [Scottish Government Polypharmacy Guidance March 2015](#).

Stress urinary incontinence in women pelvic floor muscle exercises

7.4.3 Drugs used in urological pain

- ☒ Pentosan polysulfate sodium capsules (Elmiron®)

Alkalinisation of urine

potassium citrate
sodium bicarbonate

7.4.4 Bladder instillations and urological surgery

sodium chloride 0.9% for irrigation

Maintenance of indwelling urinary catheters

Sodium chloride 0.9% for irrigation
Solution G irrigation
Solution R irrigation

7.4.5 Drugs for erectile dysfunction

Alprostadil

- ☒ alprostadil injection, urethral application

Phosphodiesterase type-5 inhibitors

- ① sildenafil tablets
- ② vardenafil tablets (except oro-dispersible formulation)

① First choice within class

② Second choice within class

③ Third choice within class

☒ Hospital use

☒ Consultant initiation

☒ Specialist initiation

8: MALIGNANT DISEASE and IMMUNOSUPPRESSION

8.1 Cytotoxic Drugs

Use of these medicines should be in accordance with any guidelines/ protocols from [West of Scotland Cancer Network](#).

Some medicines may require a *case by case form to be completed for specific indications until a protocol is available* – [refer to local list](#)

Treatment for cytotoxic-induced side effects

Chemotherapy induced mucositis and myelosuppression

- calcium folinate tablets
- folic acid (as disodium salt) injection

Urothelial toxicity

- mesna tablets, injection

8.1.1 Alkylating drugs

- bendamustine (Levact[®]) infusion
- busulfan tablets
- chlorambucil tablets
- cyclophosphamide tablets, injection
- ifosfamide injection
- melphalan tablets, injection

8.1.2 Anthracyclines and other cytotoxic antibiotics

- bleomycin injection
- daunorubicin injection
- Liposomal formulation of daunorubicin/ cytarabine (Vyxeos[®]) infusion
- doxorubicin injection
- epirubicin injection
- idarubicin injection
- mitomycin injection
- mitoxantrone injection

8.1.3 Antimetabolites

- azacitidine injection
- capecitabine tablets
- cladribine injection
- cytarabine (*excludes lipid formulation*) injection
- Liposomal formulation of daunorubicin/ cytarabine (Vyxeos[®]) infusion
- fludarabine tablets, injection
- fluorouracil injection, infusion
- gemcitabine infusion
- mercaptopurine tablets
- methotrexate tablets, injection
- pemetrexed infusion

8.1.4 Vinca alkaloids and etoposide

- etoposide capsules, injection, infusion
- vinblastine injection
- vincristine injection
- vinorelbine capsules, injection

8.1.5 Other antineoplastic drugs

- abemaciclib tablets
- acalabrutinib capsules
- afatinib tablets
- aflibercept infusion
- alectinib capsules
- amsacrine infusion
- arsenic trioxide infusion
- atezolizumab infusion
- avelumab infusion
- blinatumomab infusion
- brigatinib tablets
- bortezomib injection
- bosutinib tablets
- brentuximab infusion
- cabazitaxel infusion
- carboplatin infusion
- carfilzomib infusion
- ceritinib capsules
- cetuximab infusion
- cisplatin infusion
- crisantaspase injection
- crizotinib capsules
- dacarbazine injection, infusion
- dacomitinib tablets
- daratumumab infusion
- Darolutamide tablets
- dasatinib tablets
- docetaxel infusion
- durvalumab infusion
- eribulin injection
- erlotinib tablets
- encorafenib capsules
- everolimus tablets
- gemtuzumab ozogamicin infusion
- gilteritinib tablets
- hydroxycarbamide capsules, solution
- ibrutinib tablets
- idelalisib tablets
- imatinib tablets
- inotuzumab ozogamicin infusion
- irinotecan infusion
- lorlatinib tablets
- midostaurin capsules
- neratinib tablets
- nilotinib capsules
- nintedanib capsules

First choice within class

Second choice within class

Third choice within class

Hospital use

Consultant initiation

Specialist initiation

- ☑☑ nivolumab infusion
- ☑☑ olaparib tablets
- ☑☑ osimertinib tablets
- ☑☑ oxaliplatin infusion
- ☑☑ paclitaxel (*includes Abraxane®*) infusion
- ☑☑ palbociclib capsules
- ☑☑ pegasparaginase injection
- ☑☑ pembrolizumab infusion
- ☑☑ pentostatin injection
- ☑☑ pertuzumab infusion
- ☑☑ pertuzumab and trastuzumab injection (Phesgo®)
- ☑☑ polatuzumab infusion
- ☑☑ ponatinib tablets
- ☑☑ procarbazine capsules
- ☑☑ raltitrexed infusion
- ☑☑ ribociclib tablets
- ☑☑ ruxolitinib tablets
- ☑☑ topotecan capsules, infusion
- ☑☑ trastuzumab (*includes subcutaneous formulation*) injection, infusion
- ☑☑ trastuzumab emtasine infusion (*Kadcyla®*)
- ☑☑ trastuzumab deruxtecan infusion (*Enhertu®*)
- ☑☑ tretinoin capsules
- ☑☑ trifluridine/ tipiracil tablets (*Lonsurf®*)
- ☑☑ tucatinib tablets
- ☑☑ venetoclax tablets

8.2 Drugs affecting the immune response

8.2.1 Antiproliferative immunosuppressants

- ☑☑ azathioprine injection
- ☑☑ azathioprine tablets
- ☑☑ mycophenolate mofetil tablets

8.2.2 Corticosteroids and other immunosuppressants

(a) corticosteroids

- dexamethasone 500 micrograms, 2mg soluble tablets, 2mg tablets
- prednisolone tablets (*excludes 25mg strength*), 5mg/5ml oral solution, soluble tablets

other immunosuppressants

- ☑☑ tacrolimus (*including Envarsus®*) capsules, tablets
- ☑☑ ciclosporin capsules
- ☑☑ ciclosporin injection

8.2.3 Anti-lymphocyte monoclonal antibodies

- ☑☑ Isatuximab infusion
- ☑☑ obinutuzumab infusion

- ☑☑ rituximab (*includes subcutaneous formulation*) injection, infusion

8.2.4 Other immunomodulating drugs

- ☑☑ interferon alfa-2b injection injection - *as per local protocol*
- ☑☑ interferon beta 1a injection
- ☑☑ peginterferon alfa-2a injection (*Pegasys®*)
- ☑☑ peginterferon alfa-2b injection (*ViraferonPeg®*)
- ☑☑ peginterferon beta-1a injection (*Plegridy®*) - *as per local protocol*
- ☑☑ dimethyl fumarate capsules (*Tecfidera®*) - *as per local protocol*
- ☑☑ diroximel fumarate capsules (*Vumerity®*) - (*case by case form requires to be completed until protocol available*)
- ☑☑ fingolimod capsules - *as per local protocol*
- ☑☑ glatiramer injection (*Brabio®*)
- ☑☑ lenalidomide capsules
- ☑☑ natalizumab infusion - *as per local protocol*
- ☑☑ ocrelizumab infusion
- ☑☑ ofatumumab injection (*Kesimpta®*) (*case by case form requires to be completed until protocol available*)
- ☑☑ panobinostat capsules
- ☑☑ pomalidomide capsules
- ☑☑ ponesimod tablets (*Ponvory®*) (*case by case form requires to be completed until protocol available*)
- ☑☑ siponimod tablets (*Mayzent®*) (*case by case form requires to be completed until protocol available*)
- ☑☑ teriflunomide tablets - *as per local protocol*
- ☑☑ thalidomide tablets
- ☑☑ axicabtagene ciloleucel infusion
- ☑☑ tisagenlecleucel infusion

BCG bladder instillation

- ☑☑ Bacillus Calmette-guerin instillation (*OncoTice®*)

8.3 Sex hormones and hormone antagonists in malignant disease

Use should be in accordance with any guidelines/ protocols from [West of Scotland Cancer Network](#)

8.3.2 Progestogens

- ☑☑ medroxyprogesterone acetate tablets
- ☑☑ megestrol acetate tablets

① First choice within class

② Second choice within class

③ Third choice within class

☑ Hospital use

☑ Consultant initiation

☑ Specialist initiation

8.3.4 Hormone antagonists

8.3.4.1 Breast Cancer

- anastrozole tablets
- fulvestrant injection
- letrozole tablets
- tamoxifen tablets
- exemestane tablets
- goserelin injection

8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists

Anti-androgen:

- bicalutamide tablets
- flutamide tablets
- abiraterone tablets
- enzalutamide capsules

Gonadorelin analogue:

- leuprorelin (*Prostap® DCS*) injection
- triptorelin injection
- degarelix (*Firmagon®*) injection

8.3.4.3 Somatostatin analogues

Short-acting:

- octreotide injection
- pasireotide injection

Long-acting:

- octreotide depot (*Sandostatin LAR®*) injection

9: NUTRITION and BLOOD

9.1 Anaemias and some other blood disorders

9.1.1 Iron-deficiency anaemias

9.1.1.1 Oral iron

ferrous fumarate tablets, liquid
ferrous sulphate tablets
sodium feredetate liquid

9.1.1.2 Parenteral iron

Use as per local guidelines:

ADTC 170: [Guideline for the treatment of Renal Anaemia](#)

ADTC 279: [Guideline for the Use of Intravenous Iron for the Treatment of Iron Deficiency Anaemia in Adults Aged ≥16 years](#)

ferric carboxymaltose (*Ferinject*®)
injection, infusion

iron isomaltoside (*Monofer*®)
injection, infusion

iron sucrose (*Venofer*®) infusion

9.1.2 Drugs used in megaloblastic anaemias

folic acid tablets
hydroxocobalamin injection

9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias

epoetin beta injection
 darbepoetin alfa injection

Iron overload

desferrioxamine injection
 deferasirox tablets (*Exjade*®)

9.1.4 Drugs used in platelet disorders

eltrombopag (*case by case form requires to be completed until protocol available*)
 romiplostim (*for patients when eltrombopag not absorbed orally - (case by case form requires to be completed until protocol available)*)
 anagrelide capsules
 lusutrombopag tablets
 avatrombopag tablets

9.1.6 Drugs used in neutropenia

filgrastim injection (*Current brand of choice Accofil*®)
 Pegfilgrastim injection

9.2 Fluids and electrolytes

9.2.1.1 Oral potassium

Sando-K® effervescent tablets

First choice within class

Second choice within class

Hospital use

Consultant initiation

Kay-Cee-L® liquid

Management of hyperkalaemia

calcium polystyrene sulphonate powder
(*Calcium Resonium*®)

sodium polystyrene sulphate powder
(*Resonium A*®)

sodium zirconium cyclosilicate powder for oral suspension – as per [SMC restriction](#)

9.2.1.2 Oral sodium and water

None recommended

Oral rehydration therapy

oral rehydration salts

9.2.1.3 Oral bicarbonate

sodium bicarbonate
 potassium bicarbonate

9.2.2 Parenteral preparations for fluid and electrolyte imbalance

refer to BNF

9.2.2.2 Plasma and plasma substitutes

Dextran 70 infusion
 Gelofusine/ Gelaspan infusion

9.3 Intravenous nutrition

Contact the hospital nutrition team for advice

9.4 Oral nutrition

9.4 Oral nutritional supplements

Refer to the separate [NHS Ayrshire & Arran Oral nutritional supplements formulary \(adults\) – primary care](#)

9.5 Minerals

9.5.1.1 Calcium supplements

calcium chloride injection
calcium gluconate injection
calcium carbonate chewable tablet
(*Adcal*®)
 calcium carbonate chewable tablet
(*Calcichew*®)
calcium carbonate effervescent tablets
(*Cacit*®)

9.5.1.2 Hypercalcaemia and hypercalciuria

cinacalcet (*not for primary hyperparathyroidism*)

9.5.1.3 Magnesium

magnesium sulphate injection
magnesium aspartate dihydrate
(*Magnaspartate*®)
Magnesium glycerophosphate 4mmol
chewable tablets

Third choice within class

Specialist initiation

9.5.2 Phosphorus

9.5.2.1 Phosphate supplements

Phosphate-Sandoz® effervescent tablets

9.5.2.2 Phosphate-binding agents

① sevelamer carbonate tablets, powder for solution

Second/ third line choice depends on patient's blood results/ tolerability

calcium acetate tablets

calcium carbonate chewable tablets (*Calcichew®*)

lanthanum carbonate chewable tablets, oral powder

sucroferric oxyhydroxide chewable tablets

9.5.4 Zinc

zinc sulphate effervescent 125mg tablets

9.6 Vitamins

9.6.1 Vitamin A

vitamin A and D capsules

9.6.2 Vitamin B group

Pabrinex® injection, infusion
pyridoxine tablets
thiamine tablets

9.6.3 Vitamin C

ascorbic acid tablets

9.6.4 Vitamin D

Refer to NHS Ayrshire & Arran treatment of vitamin D deficiency & insufficiency guideline in adults

alfacalcidol tablets, oral drops

alfacalcidol injection

coleciferol 1000 unit and 25,000 unit tablets (*Stexerol D3®*)

cholecalciferol 50,000 units/ml oral solution (*InVita D3®*), when cannot swallow oral formulations

calcitriol capsules

ergocalciferol 300, 000 unit injection

calcium with coleciferol

① Accrete D3® tablets - 600 mg calcium (as calcium carbonate 1500 mg) and 10 micrograms of coleciferol (equivalent to 400 IU vitamin D3)

② Accrete D3® one a day chewable tablets - 1,000 mg calcium (as calcium carbonate) and 22 micrograms cholecalciferol (vitamin D₃ equivalent to 880IU)

Calfovit D3® sachets – where tablet or chewable tablet formulations are unsuitable

9.6.5 Vitamin E

alpha tocopheryl acetate oral suspension

9.6.6 Vitamin K

Malabsorption syndromes (water- soluble preparation required):

menadiol sodium phosphate tablets

Fat soluble formula (not malabsorption):

Phytomenadione injection

9.6.7 Multivitamin preparations

Abidec® drops

Vitamin capsules BPC

Ketovite® liquid

Forceval® capsules (*post bariatric surgery only*)

① First choice within class

② Second choice within class

③ Third choice within class

Hospital use

Consultant initiation

Specialist initiation

10: MUSCULOSKELETAL and JOINT DISEASES

10.1 Drugs used in rheumatic diseases and gout

10.1.1 Non-steroidal anti-inflammatory drugs

- ibuprofen tablets
- diclofenac sodium tablets
- naproxen tablets
- naproxen effervescent tablets (*only for patients unable to swallow naproxen tablets*)
- mefenamic acid (*gynaecological conditions only*)

Cyclo-oxygenase-2-selective inhibitors

- celecoxib
- meloxicam

10.1.2 Corticosteroids

10.1.2.1 Systemic corticosteroids

- ① prednisolone tablets (excludes 25mg strength), 5mg/5ml oral solution, soluble tablets
- ① ☑ methylprednisolone intravenous injection
- ① triamcinolone acetonide intramuscular injection

10.1.2.2 Local corticosteroid injections

- ① ☑ methylprednisolone with lidocaine (*Depo-Medrone® with lidocaine*) injection
- ① ☑ triamcinolone acetonide injection
- ① ☑ triamcinolone hexacetonide (*juvenile idiopathic arthritis only*) injection

10.1.3 Drugs that suppress the rheumatic disease process

* A combination of these medicines may be used as guided by specialists

- ① ☑ methotrexate 2.5mg tablets, pre-filled pens (*Metoject®*)
- ② ☑ hydroxychloroquine tablets
- ② ☑ leflunomide tablets
- ② ☑ sulfasalazine e/c tablets
- ③ ☑ azathioprine tablets
- ③ ☑ ciclosporin capsules - *patients should be maintained on same brand*
- ③ ☑ cyclophosphamide tablets
- ③ ☑ penicillamine tablets

Cytokine modulators

Rheumatoid Arthritis

All medicines should be prescribed as per the local guidelines for the management of rheumatoid arthritis (adults)

- ① ☑ ☑ adalimumab prefilled syringe/ pen (*Amgevita® brand of choice*)
- ① ☑ ☑ baricitinib tablets (*oral treatment*)
- ② ☑ ☑ etanercept prefilled syringe/ pen (*Benepali® brand of choice*)
- ② ☑ ☑ certolizumab prefilled syringe, pens
- ② ☑ ☑ golimumab prefilled syringe/ pen
- ② ☑ ☑ infliximab infusion (*Remsima® brand of choice*)
- ② ☑ ☑ tocilizumab infusion
- ② ☑ ☑ rituximab infusion (*Rixathon® brand of choice*)
- ② ☑ ☑ sarilumab prefilled syringe/ pen
- ③ ☑ ☑ abatacept prefilled syringe, pens

Psoriatic Arthritis

All medicines should be prescribed as per the local guidelines for the management of psoriatic arthritis (adults)

- ① ☑ apremilast tablets (*oral treatment*)
- ① ☑ ☑ secukinumab prefilled syringe/ pen
- ② ☑ ☑ adalimumab prefilled syringe/ pen (*Amgevita® brand of choice*)
- ③ ☑ ☑ etanercept prefilled syringe/ pen (*Benepali® brand of choice*)
- ③ ☑ ☑ golimumab prefilled syringe/ pen
- ③ ☑ ☑ infliximab infusion (*Remsima® brand of choice*)
- ③ ☑ ☑ certolizumab prefilled syringe, pens
- ③ ☑ ☑ ustekinumab prefilled syringe
- ③ ☑ ☑ tofacitinib tablets

Ankylosing Spondylitis

All medicines should be prescribed as per the local guidelines for the management of ankylosing spondylitis (adults)

- ① ☑ ☑ adalimumab prefilled syringe/ pen (*Amgevita® brand of choice*)
- ② ☑ ☑ secukinumab prefilled syringe/ pen
- ③ ☑ ☑ etanercept prefilled syringe/ pen (*Benepali® brand of choice*)
- ③ ☑ ☑ certolizumab prefilled syringe, pen
- ③ ☑ ☑ golimumab prefilled syringe/ pen
- ③ ☑ ☑ infliximab infusion (*Remsima® brand of choice*)

Still's disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD)

- ☑ ☑ anakinra injection - as per [SMC 2104](#)

① First choice within class

② Second choice within class

☑ Hospital use

☑ Consultant initiation

③ Third choice within class

☑ Specialist initiation

Giant Cell Arteritis (GCA) (adults)

- ☒☒ tocilizumab prefilled syringes, pens– as per [SMC 2014](#) (case by case form requires to be completed until protocol available)

10.1.4 Gout and cytotoxic-induced hyperuricaemia

Acute attacks of gout

- ① NSAID e.g diclofenac sodium
- ☒ colchicine

Long term control of gout

- ① allopurinol
- ② sulfinpyrazone
- ☒ febuxostat

10.2 Drugs used in neuromuscular disorders

10.2.1 Drugs that enhance neuromuscular transmission

- ☒ pyridostigmine bromide

10.2.2 Skeletal muscle relaxants

- baclofen
- dantrolene
- diazepam
- ☒ tizanidine

Nocturnal leg cramps

- quinine sulphate tablets

10.3 Drugs for the relief of soft-tissue disorders and topical pain relief

10.3.2 Rubefacients, topical NSAIDs, capsaicin, and poultices

- ① ibuprofen 5% gel
- ① ketoprofen 2.5% gel

Capsaicin

- capsaicin 0.075% cream (*Axsain*®) (Diabetic neuropathy only)
- capsaicin 0.025% cream (*Zacin*®)
- ☒☒ capsaicin cutaneous patch (*Qutenza*®)

Poultices

- Kaolin poultice

11: EYES

11.3 Anti-infective eye preparations

11.3.1: Antibacterials

- ① chloramphenicol eyedrops/ointment
- ② fusidic acid eyedrops
- propamidine (*Brolene*®) eyedrops/ointment
- ☒ gentamicin eye drops

Quinolones

- ① ☒ ofloxacin eye drops
- ② ☒ ciprofloxacin eye drops

11.3.2: Antifungals

Consultant ophthalmology initiation – contact pharmacy for advice on products available

11.3.3: Antivirals

- ☒ ganciclovir 0.15% w/w eye gel

11.4 Corticosteroids and other anti-inflammatory preparations

11.4.1: Corticosteroids

- ☒ betamethasone 0.1% eye drops
- ☒ dexamethasone 0.1% eye drops (*Maxidex*®)
- ☒ dexamethasone 0.1% preservative free eye drops
- ☒ dexamethasone 0.1% with neomycin and polymyxin B eye ointment (*Maxitrol*®)
- ☒ fluorometholone 0.1% eye drops (FML®)
- ☒ prednisolone sodium phosphate 0.5% eye drops, preservative free single dose drops
- ☒ prednisolone acetate 1% eye drops (*Predforte*®)

Intra-vitreous corticosteroids

- ☒ ☒ dexamethasone (*Ozurdex*®) (*awaiting protocol for use*)
- ☒ ☒ fluocinolone acetonide (*Iluvien*®) (*awaiting protocol for use*)

11.4.2 Other anti-inflammatory preparations

- ① sodium cromoglicate eye drops
- ② olopatadine eye drops

11.5 Mydriatics and cycloplegics

Antimuscarinics:

- ☒ atropine preservative-free eye drops
- cyclopentolate eye drops
- tropicamide eye drops

Sympathomimetic:

- ☒ phenylephrine eye drops

11.6 Treatment of glaucoma

a) Prostaglandin analogue

- ① ☒ latanoprost 50 micrograms/ml eye drops
- ② ☒ bimatoprost 300 micrograms/ml eye drops

Preservative free prostaglandin analogue

Restricted to use in patients with a proven sensitivity to preservatives e.g. benzalkonium chloride

- ① ☒ latanoprost 50 micrograms/ml preservative free eye drops
- ② ☒ bimatoprost 300 micrograms/ml preservative free eye drops

Combination products

Restricted to use in patients where compliance or the excessive number of drops they need to administer daily is a problem

- ① ☒ latanoprost 50 micrograms/ml with timolol 5mg/ml eye drops
- ② ☒ bimatoprost 300 micrograms/ml with timolol 5mg/ml eye drops (*Ganfort*®)

Preservative free combination products

Restricted to use in patients with a proven sensitivity to preservatives e.g. benzalkonium chloride

- ① ☒ latanoprost 50 microgram/ml with timolol 5mg/ml preservative free eye drops (*Fixapost*®)
- ② ☒ bimatoprost 300 micrograms/ml with timolol 5mg/ml preservative free eyedrops (*Ganfort*®)

b) Beta-blockers

- ① ☒ timolol 0.25% eye drops
- ② ☒ betaxolol 0.25%, 0.5% eye drops

Long acting beta blocker – where compliance an issue

- ① ☒ timolol 0.25% eye gel (*Timoptol LA*®)

Preservative free beta-blockers

Restricted to use in patients with a proven sensitivity to preservatives e.g. benzalkonium chloride

- ① timolol 0.1% unit dose eye gel (Tiopex®)

c) Sympathomimetics

- ① brimonidine 0.2% eye drops

Combination products

Restricted to use in patients where compliance or the excessive number of drops they need to administer daily is a problem

- brimonidine 0.2% with timolol 0.5% eye drops (Combigan®)
- brinzolamide 1% with brimonidine tartrate 0.2% eye drops (Simbrinza®)

d) Carbonic anhydrase inhibitors and systemic drugs

- ① brinzolamide 10mg/ml eye drops
- ② dorzolamide 2% eye drops

Preservative free prostaglandin analogue

Restricted to use in patients with a proven sensitivity to preservatives e.g. benzalkonium chloride

- ① dorzolamide 2% preservative free eye drops

Combination products

Restricted to use in patients where compliance or the excessive number of drops they need to administer daily is a problem

- ① brinzolamide 1% with timolol 0.5% eye drops
- ② dorzolamide 2% with timolol 0.5% eye drops

Preservative free combination products

Restricted to use in patients with a proven sensitivity to preservatives e.g. benzalkonium chloride

- dorzolamide 2% with timolol 0.5% preservative free eye drops

Systemic drugs

- ① acetazolamide tablets, modified release capsules
- acetazolamide injection

e) Miotics

- ① pilocarpine 2%, 4% eye drops

Preservative free miotics

Restricted to use in patients with a proven sensitivity to preservatives e.g. benzalkonium chloride

- ① pilocarpine 2% preservative free eye drops

11.7 Local anaesthetics

- oxybuprocaine eye drops
- tetracaine eye drops
- lidocaine and fluorescein eyedrops
- proxymetacaine eyedrops

11.8 Miscellaneous Ophthalmic Preparations

11.8.1 Tear deficiency, ocular lubricants and astringents

Options for patients with mild to moderate dry eyes

- ① Hypromellose 0.3% eye drops (preservative free preparations excluded)
- ② Carbomer 980 0.2% (Clinitas® Carbomer gel) ophthalmic gel
- liquid paraffin preservative free eye ointment (Lacri-lube®)

Preservative-free formulations are available, for patients in whom the above options are not suitable:

- sodium hyaluronate 0.03% preservative free eyedrops (HYLO-Fresh®) NB: bottle can be used for upto 6 months after opening
- sodium hyaluronate 0.1% preservative free eyedrops (HYLO-Tear®) NB: bottle can be used for upto 6 months after opening
- liquid paraffin preservative free eye ointment (Lacri-lube®)

Options for patients with severe dry eyes

- sodium hyaluronate 0.2% preservative free eyedrops (HYLO-Forte®) NB: bottle can be used for upto 6 months after opening
- VitA-POS® preservative free eye ointment
- ciclosporin eyedrops (Ikervis®) - severe keratitis in adults with dry eye disease which has not improved despite treatment with tear substitutes

11.8.2 Ocular diagnostic and peri-operative preparations and photodynamic treatment

Ocular diagnostic preparations

- fluorescein sodium eye drops

Ocular peri-operative drugs

- ④ ④ apraclonidine eye drops
- ④ ④ cefuroxime injection (*Aprokam*®)
- ④ ④ diclofenac sodium eye drops
- ④ ④ flurbiprofen sodium eye drops
- ④ ④ ketorolac trometamol eye drops
- ④ ④ Miochol-E® intra-ocular irrigation solution
- ④ ④ Mydrane® (*tropicamide, phenylephrine hydrochloride and lidocaine hydrochloride*) intra-cameral injection
- ④ ④ nepafenac eye drops
- ④ ④ sodium hyaluronate injection
- ④ ④ balanced Salt Solution

Subfoveal Choroidal neovascularisation

- ④ ④ ranibizumab
- ④ ④ aflibercept

12: EAR, NOSE and OROPHARYNX

12.1 Drugs acting on the ear

12.1.1 Otitis externa

Anti-inflammatory preparations

- ① betamethasone sodium phosphate 0.1% ear drops

Antibacterial preparations

- ☒ ciprofloxacin 2mg/mL ear drops single dose container (Cetraxal®)

Anti-inflammatory with anti-bacterial preparations

If ear drum not perforated

- ① Otomize® (dexamethasone 0.1%, neomycin sulfate 3250units/ml, glacial acetic acid 2%) ear spray
- ① Sofradex® (dexamethasone 0.05%, framycetin 0.5%, gramicidin 0.05%) ear drops
- ② ☒ gentamicin 0.3% with hydrocortisone 1% ear drops

If ear drum perforated or suspected perforation – specialist use

Although contra-indicated by manufacturers due to risk of Ototoxicity, ENT-UK Consensus statement 2007 states safe to use in patients with perforated eardrums

- ①☒ Sofradex® (dexamethasone 0.05%, framycetin 0.5%, gramicidin 0.05%) ear drops (off-label use)

Fungal infection suspected

- ① clotrimazole 1% solution

12.1.2 Otitis media

- ☒ ciprofloxacin 3mg/mL with dexamethasone 1mg/mL ear drops (Cilodex®) - treatment of acute otitis media in patients with tympanostomy tubes (AOMT)

12.1.3 Removal of earwax

- ① sodium bicarbonate 5% ear drops
- ① olive oil ear drops

12.2 Drugs acting on the nose

12.2.1 Drugs used in nasal allergy

- ① beclometasone dipropionate 50 microgram per actuation nasal spray
- ① mometasone furoate 27.5 micrograms per actuation nasal spray

Anti-histamines

- ① azelastine 0.1% nasal spray

Combination preparation

- ① azelastine hydrochloride 137micrograms plus fluticasone propionate 50micrograms per actuation nasal spray (Dymista®)

Nasal polyps

- ① ☒ betamethasone sodium 0.1% nasal drops
- ① ☒ fluticasone 400 microgram (Flixonase® Nasule®)

12.2.2 Topical nasal decongestants

- ① xylometazoline 0.1% nasal drops, nasal spray

Antimuscarinics

- ① Ipratropium bromide 21 micrograms per metered dose nasal spray

12.2.3 Nasal preparations for infection

- ① Naseptin® nasal cream
- ② Mupirocin 2% nasal ointment (Bactroban Nasal®) - eradication of staphylococci only

12.3 Drugs acting on the oropharynx

12.3.1 Drugs for oral ulceration and inflammation

Aphthous ulcers:

- ① Benzydamine oral rinse ± chlorhexidine gluconate mouthwash

Betamethasone mouthwash (0.5mg tablet dissolve in 10ml of water)

Oral ulceration

- hydrocortisone sodium succinate 2.5mg lozenge
- Gelclair® oral gel (use if mouth dry and unable to tolerate Adcortyl®)

12.3.2 Oropharyngeal anti-infective drugs

Oral thrush

- ① nystatin 100,000 units/ml oral suspension

① First choice within class

② Second choice within class

③ Third choice within class

☒ Hospital use

☒ Consultant initiation

☒ Specialist initiation

12.3.3 Lozenges, sprays and gels

No products recommended

12.3.4 Mouthwashes, gargles and dentifrices

- ① fluoride toothpaste, mouthwash, gel
- ① sodium chloride mouthwash (*edentulous*)
- ① chlorhexidine gluconate mouthwash
(*patient is dentate and unable to brush teeth or at high risk of secondary bacterial infections*)

12.3.5 Treatment of dry mouth

- ① Biotene Oral Balance® gel
- ① Saliva stimulating tablets (patients with residual salivary function)
- ② AS Saliva Orthana® spray

Lip care

- ① hydroxymethylcellulose lubricating jelly
e.g. KY jelly
- ② Biotene Oral Balance® gel

13: SKIN

13.2.1 Emollients (moisturisers)

- ① Hydromol® ointment
- Zeroveen® cream –useful for application to face
- Doublebase® gel (excludes Dayleve gel)
- QV® cream
- white soft paraffin 50%/ liquid paraffin 50%
- Zerobase® cream

13.2.1.1 Emollient bath and shower preparations

- Hydromol® emollient bath and shower emollient
- QV® wash, bath oil

Bath and shower preparations with antimicrobials

- Oilatum Plus® bath additive
- Dermol® 500 & 600 lotion (excludes Dermol® 200)

13.2.2 Barrier preparations

- ① Conotrane® cream
- Sudocrem® cream
- zinc & castor oil ointment

Skin Protectors

- Cavilon® cream, sachet and spray

13.3 Topical local anaesthetics and antipruritics

- calamine cream
- crotamiton cream
- menthol 1% in aqueous cream

13.4 Topical corticosteroids

Mild corticosteroid:

- ① hydrocortisone 0.5%, 1% cream, ointment

Moderately potent corticosteroid:

- clobetasone butyrate 0.05% cream, ointment (available as generic preparation or branded Eumovate®)
- betamethasone valerate 0.025% (Betnovate-RD®) cream, ointment (note if 100g sizes required, then Betnovate-RD® is the most cost effective option)

Potent corticosteroid:

- betamethasone valerate 0.1% cream, ointment (available as generic preparation or branded Betnovate®)
- fluocinolone acetonide 0.025% (Synalar®) gel
- mometasone furoate 0.1% cream, ointment, lotion (available as generic preparation or Elocon®)
- betamethasone dipropionate 0.05%/ salicylic acid 3% (Diprosalic®) ointment
- betamethasone valerate 0.1% (Betacap®) scalp solution

Very potent corticosteroid:

- clobetasol propionate 0.05% cream, ointment, scalp application (available as generic preparation or branded Dermovate®)

Topical corticosteroid with antimicrobials

Mild potency

- hydrocortisone 1%, clotrimazole 1% (Canesten HC®) cream
- hydrocortisone 1%, miconazole 2% (Daktacort®) cream, ointment
- hydrocortisone 1%, fusidic acid 2% (Fucidin H®) cream (NB: caution with use due to increased risk of antibiotic resistance)
- hydrocortisone 0.5%, nystatin 100,000 units/g (Timodine®) cream

Moderate potency

- clobetasone butyrate 0.05%, oxytetracycline 3%, nystatin 100,000units/ g (Trimovate®) cream

Potent

- betamethasone valerate 0.1%, clioquinol 3% cream, ointment
- betamethasone valerate 0.1%, fusidic acid 2% (Fucibet®) cream (Note: consider for a maximum of 14 days as longer use increases the risk of antibiotic resistance)
- flucinolone acetate 0.025%, clioquinol 3% (Synalar C®) cream, ointment

13.5 Preparations for eczema and psoriasis

13.5.1 Preparations for eczema

- ichthammol 1% ointment/ paste
- zinc paste bandages
- wet wraps using Comfast bandages
- ZipZoc® bandage

① First choice within class

② Second choice within class

③ Third choice within class

🏥 Hospital use

👤 Consultant initiation

🏥 Specialist initiation

13.5.2 Preparations for psoriasis

Vitamin D and analogues

- calcitriol ointment
- calcipotriol ointment, scalp solution (*avoid application to the face*)
- calcipotriol and betamethasone dipropionate ointment, gel (NB: *should only use for a maximum of 4 weeks (scalp) or 8 weeks ("non-scalp" areas), see full formulary for additional notes*)

Tars

- Exorex® lotion
- Psoriderm® cream
- Sebco® scalp ointment

Oral retinoids for psoriasis

- ☒ ☒ acitretin capsules

13.5.3 Drugs affecting the immune response

- ☒ ciclosporin capsules, oral solution
- ☒ methotrexate tablet, injection
- ☒ tacrolimus ointment

Cytokine modulators

- ☒ ☒ adalimumab (*Amgevita® brand of choice*)
(*as per local protocols; for hidradenitis suppurativa -case by case form requires to be completed until protocol available*)
- ☒ ☒ etanercept injection (*Benepali® brand of choice*)
(*as per local protocols*)
- ☒ ☒ ixekizumab injection (*case by case form requires to be completed until protocol available*)

13.6 Acne and rosacea

13.6.1 Topical preparations for acne

Benzoyl peroxide and azelaic acid

- ① benzoyl peroxide (*use 2.5% or 5% depending on tolerability*)

Topical retinoids and related preparations for acne

- adapalene cream
- adapalene 0.1% and benzoyl peroxide 2.5% (*Epiduo®*) gel
- tretinoin 0.025%, clindamycin (as phosphate) 1% (*Treclin®*) gel

Topical antibacterials for acne

- Zineryt® topical solution
- Duac® Once daily gel

13.6.2 Oral preparations for acne

Oral antibacterials for acne

- ① oxytetracycline
- ① lymecycline
- ② doxycycline
- ② erythromycin

Hormone treatment for acne

- Co-cyprindiol (*cyproterone acetate 2mg, ethinylestradiol 35micrograms*) tablets

Oral retinoid for acne

- ☒ ☒ isotretinoin capsules

13.6.3 Topical preparations for rosacea

- azelaic acid (*Finacea®*) gel
- metronidazole 0.75% cream, gel
- brimonidine gel (*moderate to severe persistent facial erythaema associated with rosacea*)
- ivermectin cream (*moderate to severe inflammatory lesions of rosacea where other topical treatments are unsuitable or ineffective*).

13.7 Preparations for warts and calluses

- Glutarol® solution
- Occlusal® application
- Salatac® gel

Anogenital warts

- ① podophyllum solution
- ☒ imiquimod cream *restricted to Sexual Health initiation*
- ☒ camellia sinensis (green tea leaf extract) (*Catephen®*) ointment – *restricted to Sexual Health initiation*

13.8 Sunscreens and camouflagers

13.8.1 Sunscreen preparations

Only preparations with SPF above 30 should be prescribed

- Sunsense® Ultra Lotion (SPF 50+)
- Uvistat® cream (SPF 30 or 50)

Photodamage

- ① diclofenac gel 3% (*Solaraze®*)
- ☒ ② fluorouracil cream (*Efudix®*)
- ☒ fluorouracil 0.5% / salicylic acid 10% cutaneous solution (*Actikerall®*)
- ☒ imiquimod cream (*Aldara®*)

- ☒ ☒ methyl aminolevulinate cream

13.9 Shampoos and other preparations for scalp and hair conditions

- Capasal® shampoo
- ketoconazole shampoo
- Sebco® scalp ointment

① First choice within class

② Second choice within class

③ Third choice within class

☒ Hospital use

☒ Consultant initiation

☒ Specialist initiation

Hirsutism

eflornithine cream

13.10 Anti-infective skin preparations

13.10.1 Anti-bacterial preparations

Topical antibiotics

mupirocin cream, ointment
silver sulfadiazine cream
fusidic acid cream
metronidazole cream

13.10.2 Antifungal preparations

Yeast infections

① clotrimazole cream
② miconazole cream

Dermatophyte infections

① terbinafine cream
amorolfine cream, nail lacquer

13.10.3 Antiviral preparations

aciclovir cream, tablets
penciclovir cream (*labial herpes simplex only*)

13.10.4 Parasitocidal preparations

Refer to local treatment guidelines for further information

Scabies

permethrin 5% dermal cream
malathion 0.5% aqueous liquid

Head lice:

malathion 0.5% aqueous liquid
dimethicone 4% lotion (Hedrin®)
dimeticone 92% dual formula spray (NYDA®)

13.10.5 Preparations for minor cuts and abrasions

magnesium sulphate paste

13.11 Skin cleansers, antiseptics and desloughing agents

Refer to Control of Infection manual

13.11.6 Oxidisers and dyes

potassium permanganate tablets (*refer to separate guidelines*)
hydrogen peroxide cream

13.12 Antiperspirants

aluminium chloride hexahydrate

13.13.1 Wound management products

Refer to separate primary and secondary wound care guidelines/ formulary, available on AthenA

① First choice within class

🏥 Hospital use

② Second choice within class

🏥 Consultant initiation

③ Third choice within class

🏥 Specialist initiation

15: ANAESTHESIA

15.1 General anaesthesia

- ① sodium citrate liquid

15.1.1 Intravenous anaesthetics

- ① propofol injection
- ② ketamine injection
- thiopental injection
- etomidate injection

15.1.2 Inhalational anaesthetics

- ① sevoflurane
- ② desflurane
- nitrous oxide

15.1.3 Inhalation analgesia

- Entonox® or Equanox® (containing 50% nitrous oxide and 50% oxygen)

15.1.3 Antimuscarinic drugs

- atropine sulphate injection
- glycopyrronium bromide injection
- hyoscine hydrobromide injection

15.1.4 Sedative and analgesic peri-operative drugs

15.1.4.1 Benzodiazepines

Pre-operative sedation

- diazepam tablets, oral solution, injection, rectal solution tubes
- temazepam tablets, oral solution
- lorazepam tablets

Intravenous sedation (specialist training required)

- midazolam injection

15.1.4.2 Peri-operative analgesics

Non-opioid analgesics

- diclofenac sodium injection
- ketorolac trometamol injection

Opioid analgesics

Also refer to section 4.7

- alfentanil injection
- fentanyl injection
- remifentanil injection
- Paracetamol infusion

15.1.5 Neuromuscular blocking agents

Non-depolarising neuromuscular blocking drugs

- ① rocuronium bromide injection
- ② vecuronium bromide
- atracurium besilate injection
- mivacurium injection

- cisatracurium injection

Depolarising neuromuscular blocking drugs

- ① suxamethonium chloride injection

15.1.6 Drugs for reversal of neuromuscular blockade

- ① neostigmine with glycopyrronium bromide injection
- ② sugammadex-injection

15.1.7 Antagonists for central and respiratory depression

Opioid receptor antagonist

- ① naloxone injection

Benzodiazepine antagonist

- ① flumazenil injection

Respiratory stimulants

- doxapram injection

15.1.8 Drugs for malignant hyperthermia

- ① dantrolene sodium injection

15.2 Local anaesthesia

- ① Tetracaine gel (Ametop®)
- ② Emla® cream (containing lidocaine 2.5% and prilocaine 2.5%)

chloroprocaine hydrochloride injection

lidocaine injection

lidocaine with adrenaline injection

lidocaine with phenylephrine

prilocaine hydrochloride injection

prilocaine hydrochloride (Prilotekal® hyperbaric solution for injection)

bupivacaine with glucose (Marcain® Heavy)

levobupivacaine

lidocaine patches (post herpetic neuralgia only)

- mepivacaine injection (podiatry use only)